Sophisticated Sequencing Techniques Used to Study Ancient Humans
|
By LabMedica International staff writers Posted on 20 Jan 2010 |
DNA that is left in the remains of long-dead plants, animals, or humans allows a direct look into the history of evolution. Up to now, studies of this sort on ancestral members of the human species have been hindered by scientists' inability to differentiate the ancient DNA from modern-day human DNA contamination. Now, new research overcomes this hurdle and shows how it is possible to directly analyze DNA from a member of our own species who lived around 30,000 years ago.
DNA is a robust molecule and can persist, conditions permitting, for several tens of thousands of years. Such ancient DNA provides scientists with unique possibilities to directly see into the genetic composition of organisms that have long since vanished from the Earth. Using ancient DNA extracted from bones, the biology of extinct animals as well as of ancient humans, such as the Neanderthals, has been successfully studied in recent years.
This ancient DNA application could not be easily applied to ancient members of the human species. This is because the ancient DNA fragments are multiplied with customized molecular probes that target specific DNA sequences. These probes, however, cannot distinguish whether the DNA they recognize comes from the ancient human sample or was introduced much later, for instance, by the archaeologists who handled the bones. Therefore, conclusions about the genetic make-up of ancient humans were filled with uncertainty.
Using the remains of humans that lived in Russia approximately 30,000 years ago, research by Dr. Svante Pääbo and his colleagues from the Max-Planck Institute for Evolutionary Anthropology (Leipzig, Germany) and published online on December 31, 2009, in the journal Current Biology, now make use of the latest DNA sequencing techniques to overcome this problem. These techniques, known as "second-generation sequencing,” enable the researchers to "read” directly from ancient DNA molecules, without having to use probes to multiply the DNA. Moreover, they can read from very short sequence fragments that are typical of DNA ancient remains because over time the DNA strands tend to degrade.
By contrast, DNA that is younger and only recently encountered the sample would consist of much longer fragments. This and other characteristics, such as the chemical damage incurred by ancient as opposed to modern DNA, effectively enabled the researchers to differentiate between genuine ancient DNA molecules and modern contamination. "We can now do what I thought was impossible just a year ago-- determine reliable DNA sequences from modern humans--but this is still possible only from very well preserved specimens,” stated Dr. Pääbo.
The application of this technology to the remains of members of the human species that lived tens of thousands of years ago now opens a possibility to address questions about the evolution and prehistory of ancient humans that were not possible with previous methods; for instance, whether the humans living in Europe 30,000 years ago are the direct ancestors of present-day Europeans or whether they were later replaced by immigrants that brought new technology such as agriculture with them.
Related Links:
Max-Planck Institute for Evolutionary Anthropology
DNA is a robust molecule and can persist, conditions permitting, for several tens of thousands of years. Such ancient DNA provides scientists with unique possibilities to directly see into the genetic composition of organisms that have long since vanished from the Earth. Using ancient DNA extracted from bones, the biology of extinct animals as well as of ancient humans, such as the Neanderthals, has been successfully studied in recent years.
This ancient DNA application could not be easily applied to ancient members of the human species. This is because the ancient DNA fragments are multiplied with customized molecular probes that target specific DNA sequences. These probes, however, cannot distinguish whether the DNA they recognize comes from the ancient human sample or was introduced much later, for instance, by the archaeologists who handled the bones. Therefore, conclusions about the genetic make-up of ancient humans were filled with uncertainty.
Using the remains of humans that lived in Russia approximately 30,000 years ago, research by Dr. Svante Pääbo and his colleagues from the Max-Planck Institute for Evolutionary Anthropology (Leipzig, Germany) and published online on December 31, 2009, in the journal Current Biology, now make use of the latest DNA sequencing techniques to overcome this problem. These techniques, known as "second-generation sequencing,” enable the researchers to "read” directly from ancient DNA molecules, without having to use probes to multiply the DNA. Moreover, they can read from very short sequence fragments that are typical of DNA ancient remains because over time the DNA strands tend to degrade.
By contrast, DNA that is younger and only recently encountered the sample would consist of much longer fragments. This and other characteristics, such as the chemical damage incurred by ancient as opposed to modern DNA, effectively enabled the researchers to differentiate between genuine ancient DNA molecules and modern contamination. "We can now do what I thought was impossible just a year ago-- determine reliable DNA sequences from modern humans--but this is still possible only from very well preserved specimens,” stated Dr. Pääbo.
The application of this technology to the remains of members of the human species that lived tens of thousands of years ago now opens a possibility to address questions about the evolution and prehistory of ancient humans that were not possible with previous methods; for instance, whether the humans living in Europe 30,000 years ago are the direct ancestors of present-day Europeans or whether they were later replaced by immigrants that brought new technology such as agriculture with them.
Related Links:
Max-Planck Institute for Evolutionary Anthropology
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








